Abstract Number: 0392 • ACR Convergence 2025
Clinical Indicators of Methotrexate Response in Juvenile Idiopathic Arthritis (JIA) and JIA with Uveitis (JIA-U)
Background/Purpose: Patients with JIA are at high risk for development of chronic anterior uveitis (CAU), impacting 10-20% of this population. Although methotrexate (MTX) is the…Abstract Number: 0364 • ACR Convergence 2025
Group-Based Medical Mistrust and Logistical Factors Influencing Rheumatology Clinical Trial Enrollment: A Single-Center Cross-Sectional Survey
Background/Purpose: Clinical trials are the cornerstone of evidence-based rheumatology, yet enrolling and retaining a representative patient cohort remains challenging. While underrepresentation of underserved minorities is…Abstract Number: 0379 • ACR Convergence 2025
Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study
Background/Purpose: Residual fatigue highlights an unmet prevalent1 need in rheumatoid arthritis (RA) patients despite achieving remission of disease activity according to activity indices (DAS28).We examine…Abstract Number: 0333 • ACR Convergence 2025
Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees
Background/Purpose: Artificial intelligence (AI) rapid advancement opens new opportunities in the field of rheumatology. With better imaging, AI may help find early osteoarthritic changes that…Abstract Number: 0413 • ACR Convergence 2025
Improving Access to Timely Joint Injections for Pediatric Rheumatology Patients – A Quality Improvement Initiative
Background/Purpose: Timely treatment for juvenile idiopathic arthritis (JIA) is essential for disease remission and decreasing risk of long-term morbidity. Intra-articular corticosteroid joint injections can treat…Abstract Number: 0291 • ACR Convergence 2025
Acute onset inflammatory myositis: Clinical features and survival.
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are characterized by subacute onset symmetric proximal muscle weakness, with occasional extra-muscular involvement, leading to significant morbidity and mortality. Acute…Abstract Number: 0407 • ACR Convergence 2025
The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort
Background/Purpose: Childhood chronic non-infectious uveitis (cNIU) is a sight-threatening condition that can lead to blindness if not appropriately treated. cNIU is typically associated with Juvenile…Abstract Number: 0399 • ACR Convergence 2025
External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis
Background/Purpose: Administrative claims databases enable research in large populations with JIA. We previously showed that machine learning (ML)-based algorithms accurately identify new JIA diagnoses within…Abstract Number: 0309 • ACR Convergence 2025
A Composite Cumulative Cartilage Damage Metric Predicts Incident Symptomatic Knee OA: Data from the Osteoarthritis Initiative
Background/Purpose: Cartilage defects are a hallmark of OA progression. We previously developed a composite MRI-based metric that combines cartilage damage from 6 anatomical regions throughout…Abstract Number: 0351 • ACR Convergence 2025
Experience with romosozumab in women with osteoporosis at high risk of fracture in real-world clinical practice
Background/Purpose: Romosozumab (RMZ) is a recently approved dual-acting drug which has been shown to reduce fracture risk in patients with osteoporosis (OP) in clinical trials.…Abstract Number: 0315 • ACR Convergence 2025
Cross-sectional analysis of association between erosive hand osteoarthritis and cardiovascular disease.
Background/Purpose: Erosive hand osteoarthritis (EHOA) is an inflammatory subtype of hand OA that causes subchondral bone erosion and cortical destruction, often resulting in debilitating symptoms.…Abstract Number: 0305 • ACR Convergence 2025
From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
Background/Purpose: Inclusion body myositis (IBM) is a progressive and severe inflammatory muscle disease that primarily affects adults over 50 years of age. It presents with…Abstract Number: 0416 • ACR Convergence 2025
Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting
Background/Purpose: We aimed to study the outcomes (remission, flare, and adverse events) of biological disease-modifying anti-rheumatic drugs (bDMARD) in children with JIA from a low-middle-income…Abstract Number: 0408 • ACR Convergence 2025
Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus
Background/Purpose: There is a profound need to improve outcomes in children with systemic lupus erythematosus (SLE) given this disease is complicated by significant morbidity. Disparities…Abstract Number: 0398 • ACR Convergence 2025
Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common pediatric rheumatic disease. Tumor necrosis factor inhibitors (TNFi) are key treatments in non-systemic JIA (sJIA), but…
- « Previous Page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- …
- 2607
- Next Page »
